Sepsis Clinical Trial
— Code SepsisOfficial title:
Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care
Verified date | February 2024 |
Source | Intermountain Health Care, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sepsis is a life-threatening complication of infection that can be difficult to recognize and treat promptly. Timely administration of antibiotics for emergency department (ED) patients with sepsis is challenging. The goal of this study is to determine the potential effectiveness and unintended consequences of reorganizing ED care for patients with suspected sepsis.
Status | Completed |
Enrollment | 180402 |
Est. completion date | December 28, 2023 |
Est. primary completion date | January 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria (overall): 1. Adult (age =18 years) 2. ED patient at Intermountain Medical Center, Utah Valley Hospital, Dixie Regional Medical Center 3. Arrival to study emergency department (ED) during study period of 11/13/2018 to 2/12/2021. Exclusion criteria (overall): (1) Trauma patient |
Country | Name | City | State |
---|---|---|---|
United States | Intermountain Medical Center | Murray | Utah |
United States | Utah Valley Hospital | Provo | Utah |
United States | Dixie Regional Medical Center | Saint George | Utah |
Lead Sponsor | Collaborator |
---|---|
Intermountain Health Care, Inc. | National Institute of General Medical Sciences (NIGMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Antibiotic Utilization' | Fraction of all ED patients receiving antibiotics within 24 hours of ED arrival | Up to 24 hours from ED arrival (an average of 6 hours) | |
Other | Adverse Effects of Antibiotics (Sepsis Patients) | Measured as the fraction of sepsis patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics | From the time of ED arrival to hospital discharge (up to 1 year, average 14 days) | |
Other | Adverse Effect of Antibiotics (All ED Patients) | Measured as the fraction of all ED patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics | From the time of ED arrival to hospital discharge (up to 1 year, average 14 days) | |
Other | New Onset Clostridium Difficile Colitis Incidence (Sepsis Patients) | Incidence of positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival among ED sepsis patients and (2) all ED patients. | Beginning 72 hours after ED arrival to 90 days after ED arrival | |
Other | New Onset Clostridium Difficile Colitis Incidence (All ED Patients) | Incidence of positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival among all ED patients. | Beginning 72 hours after ED arrival to 90 days after ED arrival. | |
Other | Antibiotic Overtreatment Rate | Fraction of ED patients with a primary hospital discharge diagnosis of congestive heart failure or venous thromboembolism and no discharge diagnosis consistent with infection who received antibiotics in the ED | Up to 24 hours from ED arrival (an average of 6 hours) | |
Other | Antibiotic Spectrum (Sepsis Patients) | Total antibiotic spectrum score for all unique antibiotics administered in first 24 hours using antibiotic spectrum scoring system developed by Stenehjem et al. (Clin Infect Dis 2016;63:1273-1280). Individual antibiotics have spectrum scores of 1 to 5, with the total score resulting from summation of the spectrum scores for each unique antibiotic administered during the first 24 hours. Minimum total 24-hour score is therefore 1 (administration of a single, minimum-spectrum antibiotic), with no maximum score. Higher values represent treatment with antibiotics with a broader spectrum. | Up to 24 hours from ED arrival (an average of 6 hours) | |
Other | Antibiotic Spectrum (All ED Patients) | Total antibiotic spectrum score for all unique antibiotics administered in first 24 hours using antibiotic spectrum scoring system developed by Stenehjem et al. (Clin Infect Dis 2016;63:1273-1280). Individual antibiotics have spectrum scores of 1 to 5, with the total score resulting from summation of the spectrum scores for each unique antibiotic administered during the first 24 hours. Minimum total 24-hour score is therefore 1 (administration of a single, minimum-spectrum antibiotic), with no maximum score. Higher values represent treatment with antibiotics with a broader spectrum. | Up to 24 hours from ED arrival (an average of 6 hours) | |
Primary | Door-to-antibiotic Time | Time from sepsis patients' emergency department arrival to intravenous (or equivalent) antibiotic initiation | Up to 24 hours from ED arrival (an average of 3 hours) | |
Secondary | All-cause 30-day Mortality | Sepsis patient death on or before the 30th day after ED arrival | 30 days after ED arrival | |
Secondary | All-cause 1-year Mortality | Sepsis patient death on or before the 365th day after ED arrival | 1 year after ED arrival | |
Secondary | All-cause In-hospital Mortality | Sepsis patient death prior to hospital discharge | From the time of admission to hospital discharge (up to 1 year, average 14 days) | |
Secondary | Hospital Charges | Amount charged to sepsis patient for their medical care during index ED visit and associated hospitalization | From the time of admission to hospital discharge (up to 1 year, average 14 days) | |
Secondary | Hospital Length of Stay | Length of time from sepsis patients' ED arrival until hospital discharge | From the time of admission to hospital discharge (up to 1 year, average 14 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |